Altimmune, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before October 6, 2025 to Discuss Your Rights – ALT

Core Viewpoint - Altimmune, Inc. is facing a class action lawsuit following the announcement of disappointing results from its IMPACT Phase 2b MASH trial of Pemvidutide, leading to a significant drop in its stock price [3][4]. Group 1: Company Overview - Altimmune, Inc. is a biopharmaceutical company involved in developing treatments for liver diseases, specifically targeting MASH (Metabolic Dysfunction-associated Steatotic Liver Disease) [3]. - The company reported topline results from the IMPACT Phase 2b MASH trial on June 26, 2025, which failed to meet statistical significance for its primary endpoint related to fibrosis reduction [3]. Group 2: Stock Performance - Following the announcement of the trial results, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in just one day [3]. Group 3: Legal Proceedings - The class period for the lawsuit is defined as August 10, 2023, to June 25, 2025, and shareholders are encouraged to register for potential recovery [3][4]. - The deadline for shareholders to seek lead plaintiff status is October 6, 2025, and there is no cost or obligation to participate in the case [4]. Group 4: Allegations - The complaint alleges that Altimmune provided inflated expectations regarding the trial results, which ultimately did not materialize due to a higher-than-expected placebo response [3]. - The company's response to the trial's failure was described as indifferent, attributing the results to the Phase 2 nature of the trial and expressing hope for better outcomes in the Phase 3 trial [3].